Abbvie Inc. Common Stock (ABBV) 52.15 $ABBV
Rectal Cancer - Pipeline Review, H1 2014
M2 - Thu May 08, 6:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer
AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C
PR Newswire Europe - Thu May 08, 5:15AM CDT
-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date([1])
Crohn's Disease - Pipeline Review, H1 2014: 83 Companies and 120 Drugs Profiled
M2 - Thu May 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8cqn8/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Crohn's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - 4SC AG - AbGenomics International, Inc. - AbbVie Inc. - Advancell - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amunix, Inc. - Aniona ApS - Antibe Therapeutics, Inc. - Aprogen, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CIMAB S.A. - CLL Pharma - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Curaxys, S.L. - Daiichi Sankyo Company, Limited - Effimune SAS Drug Profiles: - vedolizumab - infliximab biosimilar - infliximab biosimilar - remestemcel-L - vedolizumab - adalimumab - ustekinumab - vercirnon sodium - infliximab - budesonide ER - (rifabutin clarithromycin clofazimine) - infliximab biosimilar - adalimumab biosimilar - rifaximin - laquinimod sodium - tofacitinib - eldelumab - cenplacel-L - PF-04236921 - teduglutide - TNF-Kinoid - AbGn-168H - foralumab - mercaptopurine - adalimumab - vidofludimus - OvaSave - GED-0301 - zucapsaicin - Alequel For more information visit http://www.researchandmarkets.com/research/f8...ns_disease
Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Alzheimer's Disease - Pipeline Review, H1 2014: 208 Companies Profiled
M2 - Thu May 08, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x458ps/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AB Science - AC Immune SA - ALSP, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Accera, Inc. - Acumen Pharmaceuticals, Inc. - AdAlta Pty Ltd. - Addex Therapeutics - Affichem - Allinky Biopharma - AlzProtect SAS - AlzeCure Discovery AB - Alzhyme Ltd. - Alzinova AB - Amgen Inc. - Anavex Life Sciences Corp. - Angita B.V. - Aphios Corporation - Apodemus AB - Applied NeuroSolutions, Inc. - Archer Pharmaceuticals, Inc. - ArmaGen Technologies, Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Avanir Pharmaceuticals, Inc. - Avergen Ltd - Avineuro Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/x458ps/alzheimers
Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer
Cognitive Impairment - Pipeline Review, H1 2014: 40 Companies and 82 Drugs Profiled
M2 - Thu May 08, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kz65z/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AGY Therapeutics, Inc. - AbbVie Inc. - Amarantus Bioscience Holdings, Inc. - Avineuro Pharmaceuticals, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celon Pharma Sp. z o.o. - CoMentis, Inc. - D-Pharm Ltd. - Dart NeuroScience LLC - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Intra-Cellular Therapies, Inc. - Merck & Co., Inc. - Merz Pharmaceuticals GmbH - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeuroDerm Ltd. - Novartis AG - Octapharma AG - Omeros Corporation - Pacific Northwest Biotechnology, LLC - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - QR Pharma, Inc. - SK Biopharmaceuticals Co., Ltd. Drug Profiles: - MK-8931 - idursulfase - AQW-051 - GTS-21 - AVN-211 - tesamorelin acetate - eltoprazine - CHF-5074 - immune globulin (human) - ABT-126 - Peptide T - citicoline sodium - erteberel - ladostigil tartrate - sodium oligomannurarate - DAOI-B - levetiracetam - mifepristone - F-03 - Posiphen - GSK-933776 - roflumilast - ABT-560 - TTP-4000 - ITI-214 - HTL-9936 - SKL-15508 - BMS-933043 - AN-761 - PH-15 For more information visit http://www.researchandmarkets.com/research/4kz65z/cognitive
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Brain Metastasis - Pipeline Review, H1 2014: 14 Company and 19 Drug Profiles
M2 - Wed May 07, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7mxglb/brain_metastasis) has announced the addition of the "Brain Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - AngioChem Inc. - Cell Therapeutics, Inc. - Diffusion Pharmaceuticals LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Nanobiotix - Nerviano Medical Sciences S.r.l. - Philogen S.p.A. - Puma Biotechnology, Inc. - Sanofi - Spectrum Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - biOasis Technologies Inc. Drug Profiles: - neratinib - paclitaxel poliglumex - lucanthone hydrochloride - ANG-1005 - lapatinib ditosylate - veliparib - dabrafenib trametinib - dabrafenib - cabazitaxel - trastuzumab - radretumab - Trans Sodium Crocetinate - PB-357 - Therapeutic p53 Gene Agent - TAK-285 - BT-2111 - ANG-4043 - NBTX-IV - NMSE-973 For more information visit http://www.researchandmarkets.com/research/7m..._metastasi
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
Inflammatory Pain - Pipeline Review, H1 2014: 43 Company and 68 Drug Profiled
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxzwlh/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - A2M Pharma GmbH - AbbVie Inc. - Adynxx, Inc. - AnaMar AB - Anavex Life Sciences Corp. - AngioChem Inc. - Aniona ApS - Array BioPharma Inc. - Asahi Kasei Pharma Corp. - AskAt Inc. - AstraZeneca PLC - Biousian Biosystems, Inc. - Boehringer Ingelheim GmbH - CLL Pharma - DiverDrugs, S.L. - Evotec AG - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Hydra Biosciences, Inc. - RaQualia Pharma Inc. - Relevare Pharmaceuticals Ltd. - Shionogi & Co., Ltd. - Sunovion Pharmaceuticals Inc. - Takeda Pharmaceutical Company Limited - Theralpha SAS - Upsher-Smith Laboratories, Inc. - Winston Pharmaceuticals, Inc. - Zalicus Inc. - Ziarco Pharma Ltd Drug Profiles: - minocycline - grapiprant - AN-721 - ZPL-3893787 - Z-944 - lidocaine - S-120083 - SYN-1002 - Small Molecule To Antagonise P2X3 and P2X2/3 - OX-MPI - nNOS/iNOS - HC-030031 - zucapsaicin - TrkA Program - ANAVEX-1079 - ANG-2002 - AMAP-102 - RQ-00000008 - GBR-900 - CDK9 Inhibitors - Neu-P12 - CNSB-002 - CNSB-006 - AK-106 - Z-212 - PLX Cells For Neuropathic And Inflammatory Pain - THA-902 - Conolidine - AYX-3 - Project MITRA For more information visit http://www.researchandmarkets.com/research/zx...atory_pain
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
2 Health Care Stocks to Watch: Enanta Pharmaceuticals, Inc. and PDLI BioPharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 02, 5:24PM CDT
Bargain hunters have largely stayed away from health-care stocks over the last year and for good reason. Specifically, this group of stocks has generally soared to record high price-to-earnings ratios ever since 2012, making them some of the most...
Rectal Cancer - Pipeline Review, H1 2014
M2 - Thu May 08, 6:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer
AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C
PR Newswire Europe - Thu May 08, 5:15AM CDT
-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date([1])
Crohn's Disease - Pipeline Review, H1 2014: 83 Companies and 120 Drugs Profiled
M2 - Thu May 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8cqn8/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Crohn's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - 4SC AG - AbGenomics International, Inc. - AbbVie Inc. - Advancell - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amunix, Inc. - Aniona ApS - Antibe Therapeutics, Inc. - Aprogen, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CIMAB S.A. - CLL Pharma - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Curaxys, S.L. - Daiichi Sankyo Company, Limited - Effimune SAS Drug Profiles: - vedolizumab - infliximab biosimilar - infliximab biosimilar - remestemcel-L - vedolizumab - adalimumab - ustekinumab - vercirnon sodium - infliximab - budesonide ER - (rifabutin clarithromycin clofazimine) - infliximab biosimilar - adalimumab biosimilar - rifaximin - laquinimod sodium - tofacitinib - eldelumab - cenplacel-L - PF-04236921 - teduglutide - TNF-Kinoid - AbGn-168H - foralumab - mercaptopurine - adalimumab - vidofludimus - OvaSave - GED-0301 - zucapsaicin - Alequel For more information visit http://www.researchandmarkets.com/research/f8...ns_disease
Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Alzheimer's Disease - Pipeline Review, H1 2014: 208 Companies Profiled
M2 - Thu May 08, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x458ps/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AB Science - AC Immune SA - ALSP, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Accera, Inc. - Acumen Pharmaceuticals, Inc. - AdAlta Pty Ltd. - Addex Therapeutics - Affichem - Allinky Biopharma - AlzProtect SAS - AlzeCure Discovery AB - Alzhyme Ltd. - Alzinova AB - Amgen Inc. - Anavex Life Sciences Corp. - Angita B.V. - Aphios Corporation - Apodemus AB - Applied NeuroSolutions, Inc. - Archer Pharmaceuticals, Inc. - ArmaGen Technologies, Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Avanir Pharmaceuticals, Inc. - Avergen Ltd - Avineuro Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/x458ps/alzheimers
Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer
Cognitive Impairment - Pipeline Review, H1 2014: 40 Companies and 82 Drugs Profiled
M2 - Thu May 08, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kz65z/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AGY Therapeutics, Inc. - AbbVie Inc. - Amarantus Bioscience Holdings, Inc. - Avineuro Pharmaceuticals, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celon Pharma Sp. z o.o. - CoMentis, Inc. - D-Pharm Ltd. - Dart NeuroScience LLC - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Intra-Cellular Therapies, Inc. - Merck & Co., Inc. - Merz Pharmaceuticals GmbH - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeuroDerm Ltd. - Novartis AG - Octapharma AG - Omeros Corporation - Pacific Northwest Biotechnology, LLC - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - QR Pharma, Inc. - SK Biopharmaceuticals Co., Ltd. Drug Profiles: - MK-8931 - idursulfase - AQW-051 - GTS-21 - AVN-211 - tesamorelin acetate - eltoprazine - CHF-5074 - immune globulin (human) - ABT-126 - Peptide T - citicoline sodium - erteberel - ladostigil tartrate - sodium oligomannurarate - DAOI-B - levetiracetam - mifepristone - F-03 - Posiphen - GSK-933776 - roflumilast - ABT-560 - TTP-4000 - ITI-214 - HTL-9936 - SKL-15508 - BMS-933043 - AN-761 - PH-15 For more information visit http://www.researchandmarkets.com/research/4kz65z/cognitive
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Brain Metastasis - Pipeline Review, H1 2014: 14 Company and 19 Drug Profiles
M2 - Wed May 07, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7mxglb/brain_metastasis) has announced the addition of the "Brain Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - AngioChem Inc. - Cell Therapeutics, Inc. - Diffusion Pharmaceuticals LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Nanobiotix - Nerviano Medical Sciences S.r.l. - Philogen S.p.A. - Puma Biotechnology, Inc. - Sanofi - Spectrum Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - biOasis Technologies Inc. Drug Profiles: - neratinib - paclitaxel poliglumex - lucanthone hydrochloride - ANG-1005 - lapatinib ditosylate - veliparib - dabrafenib trametinib - dabrafenib - cabazitaxel - trastuzumab - radretumab - Trans Sodium Crocetinate - PB-357 - Therapeutic p53 Gene Agent - TAK-285 - BT-2111 - ANG-4043 - NBTX-IV - NMSE-973 For more information visit http://www.researchandmarkets.com/research/7m..._metastasi
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
Inflammatory Pain - Pipeline Review, H1 2014: 43 Company and 68 Drug Profiled
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxzwlh/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - A2M Pharma GmbH - AbbVie Inc. - Adynxx, Inc. - AnaMar AB - Anavex Life Sciences Corp. - AngioChem Inc. - Aniona ApS - Array BioPharma Inc. - Asahi Kasei Pharma Corp. - AskAt Inc. - AstraZeneca PLC - Biousian Biosystems, Inc. - Boehringer Ingelheim GmbH - CLL Pharma - DiverDrugs, S.L. - Evotec AG - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Hydra Biosciences, Inc. - RaQualia Pharma Inc. - Relevare Pharmaceuticals Ltd. - Shionogi & Co., Ltd. - Sunovion Pharmaceuticals Inc. - Takeda Pharmaceutical Company Limited - Theralpha SAS - Upsher-Smith Laboratories, Inc. - Winston Pharmaceuticals, Inc. - Zalicus Inc. - Ziarco Pharma Ltd Drug Profiles: - minocycline - grapiprant - AN-721 - ZPL-3893787 - Z-944 - lidocaine - S-120083 - SYN-1002 - Small Molecule To Antagonise P2X3 and P2X2/3 - OX-MPI - nNOS/iNOS - HC-030031 - zucapsaicin - TrkA Program - ANAVEX-1079 - ANG-2002 - AMAP-102 - RQ-00000008 - GBR-900 - CDK9 Inhibitors - Neu-P12 - CNSB-002 - CNSB-006 - AK-106 - Z-212 - PLX Cells For Neuropathic And Inflammatory Pain - THA-902 - Conolidine - AYX-3 - Project MITRA For more information visit http://www.researchandmarkets.com/research/zx...atory_pain
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
2 Health Care Stocks to Watch: Enanta Pharmaceuticals, Inc. and PDLI BioPharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 02, 5:24PM CDT
Bargain hunters have largely stayed away from health-care stocks over the last year and for good reason. Specifically, this group of stocks has generally soared to record high price-to-earnings ratios ever since 2012, making them some of the most...
